Special Issue "Mesenchymal Stem Cells: Immunobiology and Role in Immunomodulation and Tissue Regeneration 2.0"
Deadline for manuscript submissions: 20 December 2022 | Viewed by 118
2. Stem Cell Transplantation and Cellular Therapy Laboratory, Paediatric Onco-Haematology Division, Regina Margherita Children’s Hospital, City of Health and Science of Turin, 10126 Torino, Italy
Interests: mesenchymal stem cells; GMP production; cell therapy
Special Issues, Collections and Topics in MDPI journals
Mesenchymal stromal/stem cells (MSCs) are excellent candidates for the development of cell-based therapies in the treatment of various conditions, with over 900 clinical trials worldwide currently using MSCs to treat, among other conditions, bone/cartilage damage, diabetes, cardiovascular diseases, immune-related disorders, and neurological disorders (www.clinicaltrials.gov).
MSCs can be used to repair injured tissue by migrating them into injured sites and engrafting them to function as end-stage cells. The role of homing within MSC-based therapies, however, remains unclear, although increasing evidence suggests that their therapeutic role is actually due to immunomodulation rather than to their capacity for differentiation. It has, in fact, been shown that MSCs exert immunomodulatory and anti-inflammatory effects by regulating multiple immune cell types of both the innate and adaptive immune systems. This means that MSCs can promote neovascularization, increase angiogenesis, enhance cell viability and/or proliferation, inhibit cell death, and modulate immune responses via paracrine and cell–cell contact effects as well as through extracellular vesicles. Interestingly, despite some encouraging results from animal studies, some clinical trials have shown that MSCs have no therapeutic efficacy. Therefore, understanding the biology of MSCs and their role in treatment will be critical to determining their potential in therapeutic applications.
We invite you to contribute to this Special Issue with original research articles describing recent developments in MSC-based therapy. We are particularly interested in studies that illustrate the mechanisms underlying the protective effects of MSCs and demonstrate their role in immunomodulation and tissue regeneration.
Due to the success of the 1st edition, we would like to add more results and new insights from recent research projects. You can find the 1st edition at the following link.
Dr. Katia Mareschi
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- mesenchymal stem cells
- tissue regeration
- anti-inflammatory effects